Presentation is loading. Please wait.

Presentation is loading. Please wait.

National Institute for Pharmaceutical Technology and Education (NIPTE) Interim Risk Assessment Report.

Similar presentations


Presentation on theme: "National Institute for Pharmaceutical Technology and Education (NIPTE) Interim Risk Assessment Report."— Presentation transcript:

1 National Institute for Pharmaceutical Technology and Education (NIPTE) Interim Risk Assessment Report

2 Quality Risk Management Initiate Quality Risk Management Process Risk Assessment Risk Control Risk Review Risk Identification Risk Analysis Risk Evaluation Risk Reduction Risk Acceptance Review Events Output / Result of the Quality Risk Management Process Risk Communication Risk Management Tools unacceptable Brainstorming Elementary Cause and Effect Assignments –Fishbone (Ishikawa) diagram –Failure mode/effect table Fault tree analysis Process map Flow charts FMEA FMECA Risk ranking Risk IdentificationRisk Analysis Risk Evaluation Process sensors SOP Data flow optimization Risk Reduction From ICH Q9

3 3 Formulation Gabapentin600 mg Poloxamer 407, NF11 mg Crospovidone NF22 mg Pregelatinized corn starch, NF 60 mg Mg Stearate, NF7 mg MCC NF (Avicel PH102)100 mg Talc USP Extra-fine9 mg Hydroxypropyl cellulose 40 mg Hydroxypropyl cellulose 40 mg (Binder )

4 4 Preliminary Risk Assessment Critical quality attributes –Content uniformity –Assay –Disintegration –Physical form of API –Physical stability of API –Purity –Chemical stability –Microbiology –Appearance Unit operations –Binder solution preparation –Granulation –Drying –Granulate shipping –Blending –Compression

5 Example of Failure Mode Table SODRPN EffectCause Effect (CQA) tablets Mechanism of effectScale-upUnit opCause Disintegration Homogeneity of HPCxBlendingInadequate blending Physical form API Hydrate formation during ProcessingxGranulationTime as wet mass The (CQA) test is out of specification because (mechanism of effect). The source of the problem is in (Unit operation) and is caused by (Cause1), caused by (Cause2), caused by (Cause3).

6 Histogram of all Failure Modes Assessed (RPN values) Medium High High: > 60 Medium: = 60

7 Preliminary RPN Results: Risks sorted by Unit Operation Binder solution preparation –Number of risks assessed:11 –No high or medium risk failure modes Granulation –Number of risks assessed:75 –High risk failure modes:13 /75 –Medium risk failure modes:20 /75 Fluid bed drying –Number of risks assessed:30 –High risk failure modes:3 /30 –Medium risk failure modes:16 /30

8 QbD Approach to Formulation Optimization The original HPC grade (Klucel EXF, fine PSD) was sensitive to small changes in water content (lacking robustness) A second HPC grade (Klucel EF, larger PSD) was more robust. Similar PSDs were achieved using Klucel EF at 5.5% water as with Klucel EXF at 2.5%.

9 Comparing Granule PSD Produced from Different HPC Grades Particle size distribution Granules formed with EF and 5.5% water were similar to granules formed with EXF and 2.5% water

10 Drying of Wet Granulations with 2 Different Grades of HPC Water added 5.5%4%3%2.5%2% EF ✔✔ ✔ Little Particle Size Growth ✔ Little Particle Size Growth ✔ Little Particle Size Growth EXF No fluidization ✔✔

11 Klucel EXF vs. Klucel EF Klucel EXF Klucel EF

12 FBD Stability Concerns (Example Process Models and Design Space)

13 Summary of Drying Stability Specs Residual moisture stabilizes granules and blends from lactam formation –Some residual moisture is good to decrease lactam formation, but too much residual moisture has flow and hardness consequences, which could result in content uniformity and disintegration problems. High temperature drying results in higher lactam formation. –There was no improvement in efficiency by drying at higher temperatures due to increased cooling times, so low temperature drying is optimum.

14 Lab Scale Compression Data (Rotary Press) By changing the extragranular HPC from Klucel EF (larger PS), to Klucel EXF (Fine PS), the crushing strength threshold of 6 kp was achieved.

15 Additional Assessment Efforts Evaluate all stability data Update design space models at each scale –Develop design space model across scales Identify and document –Risks to product quality –Advantages of current methods for reducing risk Modeling Process monitoring/control


Download ppt "National Institute for Pharmaceutical Technology and Education (NIPTE) Interim Risk Assessment Report."

Similar presentations


Ads by Google